CHOLERA: PATHOGENESIS AND IMMUNOLOGY

本研究的目的是为了有助于全面了解 霍乱的发病机理和免疫学， 分子水平，并期望这将导致 制定合理有效的免疫预防措施。 作为 霍乱是一种肠毒性疾病的原型， 这些观察结果与更大的全球性问题有关， 分泌性尿道炎的症状 很明显，这种疾病，霍乱， 一种有效的免疫过程， 由霍乱弧菌在体内生长而产生的产物。 这些因素包括：定殖因素（尚未确定）;表面成分 例如脂多糖和外膜蛋白; HA/蛋白酶;其他酶;甘露糖敏感型（El Tor生物型）和 其他血凝素;鞭毛;和肠毒素。 这项建议 具体涉及： 参与霍乱弧菌粘附于肠道的因素 上皮;外膜抗原（特别是新的铁调节的 体内表达的蛋白质）;以及抗原和抗体的定义 其可以是保护性的[包括功能结构域和表位]， 免疫显性的，结合的，霍乱样（B亚基五聚体）部分， 霍乱肠毒素]。 技术包括：细菌结合研究; 用SDS-PAGE和免疫印迹进行蛋白质分离和分析; 涉及母乳中蛋白质成分的微量抗菌测定， 多克隆和单克隆抗细菌抗体; 霍乱肠毒素的单克隆抗体和合成肽 目的是开发一种合成疫苗。

The goals of this research are to contribute to the complete understanding of the pathogenesis and immunology of cholera at both the organismal and the molecular levels with the expectation that this will lead to the development of rational and effective means of immunoprophylaxis. As cholera is the prototype of an expanding number of enterotoxic enteropathies, the observations are pertinent to the larger global problem of secretory diarrheal disease. It is clear that the disease, cholera, is an effective immunizing process which presents to the human host a consortium of products elaborated by the cholera vibrios growing in vivo. These include: colonization factors (as yet undefined); surface components such as the lipopolysaccharide and outer membrane proteins; the HA/protease; other enzymes; the mannose-sensitive (El Tor biotype) and other hemagglutinins; the flagellum; and the enterotoxin. This proposal specifically addresses: the identification and characterization of factor(s) participating in adherence of Vibrio cholerae to intestinal epithelium; outer membrane antigens (particularly novel iron-regulated proteins expressed in vivo); and the definition of antigens and antibodies which may be protective [including functional domains and epitopes on the immunodominant, binding, choleragenoid (B-subunit pentamer) portion of the cholera enterotoxin]. Technology includes: bacterial binding studies; protein separation and analysis with SDS-PAGE and immunoblotting; micro-antibacterial assays involving protein components of mothers' milk, polyclonal and monoclonal antibacterial antibodies; and antitoxic monoclonal antibodies and synthetic peptides of the cholera enterotoxin with the objective of developing a synthetic vaccine.